What is Bloom Burton’s Forecast for TSE:MBX FY2025 Earnings?

Microbix Biosystems Inc. (TSE:MBX) – Bloom Burton dropped their FY2025 earnings per share (EPS) estimates for Microbix Biosystems in a note issued to investors on Thursday, June 5th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of ($0.01) per share for the year, down from their prior forecast of $0.01. Bloom Burton has a “Moderate Buy” rating on the stock. The consensus estimate for Microbix Biosystems’ current full-year earnings is $0.02 per share. Bloom Burton also issued estimates for Microbix Biosystems’ FY2026 earnings at ($0.01) EPS and FY2027 earnings at $0.01 EPS.

Microbix Biosystems Stock Performance

Microbix Biosystems stock opened at C$0.30 on Monday. Microbix Biosystems has a 12-month low of C$0.29 and a 12-month high of C$0.55. The company has a quick ratio of 5.57, a current ratio of 7.15 and a debt-to-equity ratio of 22.61. The business’s 50-day moving average price is C$0.35 and its two-hundred day moving average price is C$0.39. The stock has a market cap of C$39.51 million, a PE ratio of 11.43 and a beta of 0.34.

About Microbix Biosystems

Microbix Biosystems Inc, a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products.